Treatment possibilities for clinically localised prostate cancer include radical prostatectomy (RP), external beam radiotherapy, brachytherapy, focal therapy and active surveillance.
Conflicting and methodologically flawed observational data from the last two decades have led to uncertainty as to the best oncological option. However, recently, there has been a series of high-quality studies that point to disease specific and overall survival advantages for those men undergoing RP. This article reviews the latest evidence and argues that at the current time, RP must be considered the gold standard treatment for the majority of men with clinically localised prostate cancer.
Written by:
Stevens DJ, Sharma NL, Tewari AK, Kirby R, Sooriakumaran P. Are you the author?
Department of Physiology, Anatomy and Genetics, University of Oxford, Oxford, UK.
Reference: Curr Urol Rep. 2015 May;16(5):504.
doi: 10.1007/s11934-015-0504-z
PubMed Abstract
PMID: 25773349